title: Is GP-led follow-up feasible?
authors.forename: A B
authors.initials: AB
authors.lastname: Francken
authors.forename: J W
authors.initials: JW
authors.lastname: Hoekstra-Weebers
authors.forename: H J
authors.initials: HJ
authors.lastname: Hoekstra
mesh_terms: D003695:Delivery of Health Care / Q000379:methods*; D005194:Family Practice / Q000592:standards*; D006801:Humans; D008545:Melanoma / Q000175:diagnosis*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D017060:Patient Satisfaction; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000175:diagnosis*
references.citation: Surg Oncol Clin N Am. 2006 Apr;15(2):319-30
references.pmid: 16632217
references.citation: BMJ. 2008 Nov 20;337:a2249
references.pmid: 19022841
references.citation: Ann Surg Oncol. 2007 Jun;14(6):1924-33
references.pmid: 17357855
references.citation: Eur J Surg Oncol. 2008 May;34(5):587-92
references.pmid: 17681449
references.citation: Lancet Oncol. 2005 Aug;6(8):608-21
references.pmid: 16054572
references.citation: Australas J Dermatol. 2009 Aug;50(3):176-80
references.pmid: 19659978
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6199-206
references.pmid: 19917835
references.citation: Br J Cancer. 2010 May 11;102(10):1447-55
references.pmid: 20461089
references.citation: J Clin Oncol. 2003 Feb 1;21(3):520-9
references.pmid: 12560444
references.citation: Expert Rev Anticancer Ther. 2009 Jun;9(6):839-49
references.pmid: 19496721